MedTrace Logo

Swiss Multi-centre, Randomized, Placebo Controlled Trial of Pregabalin for Prevention of Persistent Pain in High Risk Patients Undergoing Breast Cancer Surgery

NCT03216187 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2025-10-07

No results posted yet for this study

Summary

This study will test the benefits and risks of using pregabalin perioperatively to prevent persistent postoperative pain in patients at high risk (\>30%) of developing such pain after breast cancer surgery.

Conditions

  • Persistent Postoperative Pain

Interventions

DRUG

Pregabalin

pregabalin 150 mg capsules

DRUG

Placebos

capsules identical to pregabalin but without active drug

Sponsors & Collaborators

  • University Hospital, Geneva

    collaborator OTHER

  • Centre Hospitalier Universitaire Vaudois

    collaborator OTHER

  • Insel Gruppe AG, University Hospital Bern

    collaborator OTHER

  • Benno Rehberg-Klug

    lead OTHER

Principal Investigators

  • Benno Rehberg-Klug, MD · HUG

  • Marc Suter, MD · CHUV

  • Ulrike Stamer, MD · Inselspital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-09
Primary Completion
2024-06-11
Completion
2024-11-29

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03216187 on ClinicalTrials.gov